A5086330830- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Prostate Cancer Treatment and Research
- Urologic and reproductive health conditions
- Prostate Cancer Diagnosis and Treatment
- Urological Disorders and Treatments
- Renal cell carcinoma treatment
- Esophageal Cancer Research and Treatment
- Cancer Diagnosis and Treatment
- Testicular diseases and treatments
- Economic and Financial Impacts of Cancer
- Renal and related cancers
- Radiopharmaceutical Chemistry and Applications
- Multiple and Secondary Primary Cancers
- Computational Drug Discovery Methods
- Cancer, Lipids, and Metabolism
- Genital Health and Disease
- Cancer Immunotherapy and Biomarkers
- Immune Response and Inflammation
- Appendicitis Diagnosis and Management
- Epigenetics and DNA Methylation
- Streptococcal Infections and Treatments
- Ferroptosis and cancer prognosis
- Health Systems, Economic Evaluations, Quality of Life
- Cancer-related gene regulation
University Hospital Cologne
2022-2025
University of Cologne
2022-2024
Klinik und Poliklinik für Urologie
2024
University Hospital Münster
2022
Objective Radical cystectomy (RC) is the standard of care (SOC) in BCG‐unresponsive NMIBC and associated with a significant health‐related quality‐of‐life burden. Recently, promising results have been published on Gemcitabine/Docetaxel, Pembrolizumab, Hyperthermic Intravesical Chemotherapy (HIVEC) as salvage therapy options trying to increase rate bladder preservation. Here, we performed Cost‐Effectiveness‐Analysis those treatment modalities. Patients Methods We developed Markov model from...
High risk non-muscle invasive bladder cancer (NMIBC) is usually treated with intravesical BCG-therapy. In case of BCG failure radical cystectomy (RC) the treatment choice. Nevertheless, many patients are unfit for or unwilling to undergo RC. Hyperthermic chemotherapy (HIVEC) a promising sparing therapy in such cases. It was purpose study evaluate efficacy HIVEC as well naïve shortage given contra-indications BCG.
Zusammenfassung Einleitung Die Leitlinien fordern nach Versagen der systemischen Ersttherapie des metastasierten hormonsensitiven Prostatakarzinoms (mHSPC) eine molekulare Analyse zur Identifikation therapierbarer Mutationen. Wir berichten über unsere Ergebnisse molekularen Diagnostik bei Patienten mit metastasiertem kastrationsresistenten PCA (mCRPC). und Methodik 311 mCRPC erhielten Panelanalyse von archivierten Prostatektomiepräparaten oder Computertomografie(CT)-gestützten Biopsien...
203 Background: Guidelines recommend molecular analysis to identify druggable mutations after failure of the first-line systemic therapy for metastatic prostate cancer (mPCA). We report our results diagnostics in mCRPC patients. Methods: From 2018 2023, 311 patients underwent panel archived prostatectomy samples (n=96) or CT-guided biopsies progressive metastases (n=215) using standardized NGS procedures first- second-line therapy. Mutation was initially performed with a custom "Prostate...
804 Background: The combination of enfortumab vedotin plus pembrolizumab (EV/P) has become the new standard care for advanced or metastatic urothelial carcinoma (mUC) due to its high efficacy. However, patients with active central nervous system (CNS) metastases were excluded from EV-302 trial. More recently, NECTIN-4 amplifications have been identified as genomic predictors EV response and long-term survival in mUC. Additionally, early evidence suggests that may cross blood-brain barrier be...
626 Background: Still, standard treatment of low-volume metastatic semimoma is either systemic chemotherapy or radiotherapy. Both options are associated with significant acute and long-term toxicities including mortality due to secondary malignancies in follow-up. We calculated the number potentially unnecessary cycles per hundred patients undergoing primary RPLND Chemotherapy. Methods: In follow-up COTRIMS-trial, 34 (12%) developed outfield relapses after a median 41 months. All relapsing...
691 Background: Patients with muscle invasive urothelial carcinoma (MIBC) achieving pathological complete response (pCR) upon neoadjuvant chemotherapy (NACT) have improved prognosis. Previously we did show that luminal tumors respond better to NACT (Ecke et al 2022), while chemoresistant express radioligand targets CXCR4 and FAP. First-in-Human treatment of resistant T4 MIBC using two cycles Lu 177 FAP combined one cycle pembrolizumab results in durable (Baum al, submitted). The objective...
157 Background: Cytoreductive radical prostatectomy (cRP) has emerged as an alternative treatment option to radiation therapy in men with low risk metastatic hormone sensitive prostate cancer (mHSPC). It was the purpose of our analysis evaluate if different combinations androgen deprivation have impact on pathohistological findings and oncological outcome undergoing cRP. Methods: We performed a retrospective 104 patients who underwent cRP pelvic lymph node dissection for volume mHSPC. Prior...
695 Background: Metastatic urothelial carcinoma (mUCa) is the most expensive cancer to treat on a per-patient basis, largely due need for frequent interventions and costly follow-up care. In examining first-line therapies, combinations such as enfortumab-vedotin plus pembrolizumab (EV + P) gemcitabine/cisplatin nivolumab show substantial overall survival advantages over standard treatment (SoC) of gemcitabine/cisplatin. This study presents cost-effectiveness analysis mUCa. Methods: We...
176 Background: Local complications due to infiltration and compression of adjacent organs represent significant locally advanced castration sensitive (CSPC) resistant PCA (CRPC) despite the use life prolonging agents. Methods: 139 patients with CSPC/CRPC underwent palliative pelvic surgery: radical cystoprostatectomy in n=105 (75.5%), prostatectomy continent vesicostomy n=9 (6.5%) anterior plus posterior exenteration n=25 (17.6%). All local staging via MRI small pelvis, cystoscopy...
In narrow anterior urethral strictures, the combined buccal mucosa graft (BMG) with pedicled penile skin flap (PSF) represents a well-known effective alternative to staged urethroplasty. We hypothesized that if native plate and adjacent corpus spongiosum were preserved, narrower would be needed, reinforced ventral stability could achieved without compromising surgical outcome.
Ischemia reperfusion injury (IRI) is a form of sterile inflammation whose severity determines short- and long-term graft fates in kidney transplantation. Neutrophils are now recognized as key cell type mediating early injury, which activates further innate immune responses intensifies acquired immunity alloimmunity. Since the macrolide Bryostatin-1 has been shown to block neutrophil transmigration, we aimed determine whether these findings could be translated field To study effects on...
Patients with muscle-invasive urothelial carcinoma achieving pathological complete response (pCR) upon neoadjuvant chemotherapy (NAC) have improved prognosis. Molecular subtypes of bladder cancer differ markedly regarding sensitivity to cisplatin-based and harbor FGFR treatment targets various content. The objective the present study was evaluate whether preoperative assessment molecular subtype as well target gene expression is predictive for therapeutic outcome—rate ypT0 status—to justify...
Introduction: Fournier gangrene is a life-threatening urological disease that requires rapid surgical intervention. Despite major improvements in medical therapy, the mortality of has not changed during past 25 years. To potentially improve outcome, we analyzed different processes for overall treatment gangrene. Methods: We performed retrospective single-center study 21 patients with Patients were grouped according to initial symptoms, first advice, blood tests, history, and further clinical...
Accurate staging and identification of optimal candidates for local salvage therapy, such as radical prostatectomy (SRP), is necessary to ensure care in patients with radiorecurrent prostate cancer (PCa). We aimed analyze performance magnetic resonance imaging (MRI) prostate-specific membrane antigen (PSMA)-positron emission tomography (PET)/computed (CT) predicting pathologic nonorgan confined disease (pT3) lymph node involvement (pN+) treated SRP PCa.We retrospectively reviewed the...
679 Background: In view of the efficacy FGFR targeting in early and advanced bladder cancer, as has been shown for erdafitinib THOR NORSE trial, molecular testing mutations fusions will soon become clinical routine worldwide. Therascreen approved companion diagnostic to select patients erdafitinib. However, technical problems shortages well a limited number detectable indicate need test systems that can be performed easily & fast The objective was evaluate concordance UroTyper with...